Literature DB >> 25548153

miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.

Yun Ji1, Claudia Wrzesinski2, Zhiya Yu2, Jinhui Hu3, Sanjivan Gautam3, Nga V Hawk3, William G Telford3, Douglas C Palmer2, Zulmarie Franco2, Madhusudhanan Sukumar2, Rahul Roychoudhuri2, David Clever2, Christopher A Klebanoff2, Charles D Surh4, Thomas A Waldmann5, Nicholas P Restifo2, Luca Gattinoni1.   

Abstract

Lymphodepleting regimens are used before adoptive immunotherapy to augment the antitumor efficacy of transferred T cells by removing endogenous homeostatic "cytokine sinks." These conditioning modalities, however, are often associated with severe toxicities. We found that microRNA-155 (miR-155) enabled tumor-specific CD8(+) T cells to mediate profound antitumor responses in lymphoreplete hosts that were not potentiated by immune-ablation. miR-155 enhanced T-cell responsiveness to limited amounts of homeostatic γc cytokines, resulting in delayed cellular contraction and sustained cytokine production. miR-155 restrained the expression of the inositol 5-phosphatase Ship1, an inhibitor of the serine-threonine protein kinase Akt, and multiple negative regulators of signal transducer and activator of transcription 5 (Stat5), including suppressor of cytokine signaling 1 (Socs1) and the protein tyrosine phosphatase Ptpn2. Expression of constitutively active Stat5a recapitulated the survival advantages conferred by miR-155, whereas constitutive Akt activation promoted sustained effector functions. Our results indicate that overexpression of miR-155 in tumor-specific T cells can be used to increase the effectiveness of adoptive immunotherapies in a cell-intrinsic manner without the need for life-threatening, lymphodepleting maneuvers.

Entities:  

Keywords:  adoptive immunotherapy; homeostatic cytokines; lymphodepletion; microRNA-155

Mesh:

Substances:

Year:  2014        PMID: 25548153      PMCID: PMC4299215          DOI: 10.1073/pnas.1422916112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy.

Authors:  Hyun-Il Cho; Eduardo Reyes-Vargas; Julio C Delgado; Esteban Celis
Journal:  Cancer Res       Date:  2012-02-24       Impact factor: 12.701

Review 2.  miR-155: an ancient regulator of the immune system.

Authors:  Elena Vigorito; Susan Kohlhaas; Dong Lu; Rebecca Leyland
Journal:  Immunol Rev       Date:  2013-05       Impact factor: 12.988

3.  PTPN2 attenuates T-cell lymphopenia-induced proliferation.

Authors:  Florian Wiede; Nicole L La Gruta; Tony Tiganis
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

4.  Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.

Authors:  Xin Yao; Mojgan Ahmadzadeh; Yong-Chen Lu; David J Liewehr; Mark E Dudley; Fang Liu; David S Schrump; Seth M Steinberg; Steven A Rosenberg; Paul F Robbins
Journal:  Blood       Date:  2012-05-03       Impact factor: 22.113

5.  STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.

Authors:  Katharina L Kopp; Ulrik Ralfkiaer; Lise Mette R Gjerdrum; Rikke Helvad; Ida H Pedersen; Thomas Litman; Lars Jønson; Peter H Hagedorn; Thorbjørn Krejsgaard; Robert Gniadecki; Charlotte M Bonefeld; Lone Skov; Carsten Geisler; Mariusz A Wasik; Elisabeth Ralfkiaer; Niels Ødum; Anders Woetmann
Journal:  Cell Cycle       Date:  2013-05-15       Impact factor: 4.534

6.  Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity.

Authors:  Thomas B Huffaker; Ruozhen Hu; Marah C Runtsch; Erin Bake; Xinjian Chen; Jimmy Zhao; June L Round; David Baltimore; Ryan M O'Connell
Journal:  Cell Rep       Date:  2012-11-29       Impact factor: 9.423

7.  MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer.

Authors:  Jan C Dudda; Bruno Salaun; Yun Ji; Douglas C Palmer; Gwennaelle C Monnot; Estelle Merck; Caroline Boudousquie; Daniel T Utzschneider; Thelma M Escobar; Rachel Perret; Stefan A Muljo; Michael Hebeisen; Nathalie Rufer; Dietmar Zehn; Alena Donda; Nicholas P Restifo; Werner Held; Luca Gattinoni; Pedro Romero
Journal:  Immunity       Date:  2013-04-18       Impact factor: 31.745

Review 8.  Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.

Authors:  Michael Kalos; Carl H June
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

9.  Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells.

Authors:  Yun Ji; Zoltan Pos; Mahadev Rao; Christopher A Klebanoff; Zhiya Yu; Madhusudhanan Sukumar; Robert N Reger; Douglas C Palmer; Zachary A Borman; Pawel Muranski; Ena Wang; David S Schrump; Francesco M Marincola; Nicholas P Restifo; Luca Gattinoni
Journal:  Nat Immunol       Date:  2011-11-06       Impact factor: 25.606

10.  The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling.

Authors:  Donald T Gracias; Erietta Stelekati; Jennifer L Hope; Alina C Boesteanu; Travis A Doering; Jillian Norton; Yvonne M Mueller; Joseph A Fraietta; E John Wherry; Martin Turner; Peter D Katsikis
Journal:  Nat Immunol       Date:  2013-04-21       Impact factor: 25.606

View more
  37 in total

Review 1.  Role of miRNAs in immune responses and immunotherapy in cancer.

Authors:  Maria Angelica Cortez; Simone Anfossi; Rishab Ramapriyan; Hari Menon; Semra Cemre Atalar; Maureen Aliru; James Welsh; George A Calin
Journal:  Genes Chromosomes Cancer       Date:  2019-04       Impact factor: 5.006

2.  Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.

Authors:  Thomas B Huffaker; Soh-Hyun Lee; William W Tang; Jared A Wallace; Margaret Alexander; Marah C Runtsch; Dane K Larsen; Jacob Thompson; Andrew G Ramstead; Warren P Voth; Ruozhen Hu; June L Round; Matthew A Williams; Ryan M O'Connell
Journal:  J Biol Chem       Date:  2017-09-14       Impact factor: 5.157

3.  Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.

Authors:  Sinnie Sin Man Ng; Bethany A Nagy; Shawn M Jensen; Xintao Hu; Candido Alicea; Bernard A Fox; Barbara K Felber; Cristina Bergamaschi; George N Pavlakis
Journal:  Clin Cancer Res       Date:  2016-12-16       Impact factor: 12.531

4.  MicroRNA regulation of CD8+ T cell responses.

Authors:  John D Gagnon; K Mark Ansel
Journal:  Noncoding RNA Investig       Date:  2019-08-26

5.  Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.

Authors:  Lenka V Hurton; Harjeet Singh; Amer M Najjar; Kirsten C Switzer; Tiejuan Mi; Sourindra Maiti; Simon Olivares; Brian Rabinovich; Helen Huls; Marie-Andrée Forget; Vrushali Datar; Partow Kebriaei; Dean A Lee; Richard E Champlin; Laurence J N Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-14       Impact factor: 11.205

Review 6.  Enhancing adoptive T cell immunotherapy with microRNA therapeutics.

Authors:  Yun Ji; James D Hocker; Luca Gattinoni
Journal:  Semin Immunol       Date:  2015-12-20       Impact factor: 11.130

7.  Antigenic Restimulation of Virus-Specific Memory CD8+ T Cells Requires Days of Lytic Protein Accumulation for Maximal Cytotoxic Capacity.

Authors:  Stephen A Migueles; Daniel C Rogan; Noah V Gavil; Elizabeth P Kelly; Sushila A Toulmin; Lawrence T Wang; Justin Lack; Addison J Ward; Patrick F Pryal; Amanda K Ludwig; Renata G Medina; Benjamin J Apple; Christina N Toumanios; April L Poole; Catherine A Rehm; Sara E Jones; C Jason Liang; Mark Connors
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

8.  Lactic Acid Suppresses IL-33-Mediated Mast Cell Inflammatory Responses via Hypoxia-Inducible Factor-1α-Dependent miR-155 Suppression.

Authors:  Daniel Abebayehu; Andrew J Spence; Amina Abdul Qayum; Marcela T Taruselli; Jamie J A McLeod; Heather L Caslin; Alena P Chumanevich; Elizabeth Motunrayo Kolawole; Anuya Paranjape; Bianca Baker; Victor S Ndaw; Brian O Barnstein; Carole A Oskeritzian; Scott A Sell; John J Ryan
Journal:  J Immunol       Date:  2016-08-24       Impact factor: 5.422

9.  An effective mouse model for adoptive cancer immunotherapy targeting neoantigens.

Authors:  Ken-Ichi Hanada; Zhiya Yu; Gabrielle R Chappell; Adam S Park; Nicholas P Restifo
Journal:  JCI Insight       Date:  2019-05-16

10.  miR-155 releases the brakes on antitumor T cells.

Authors:  Yun Ji; Luca Gattinoni
Journal:  Oncoimmunology       Date:  2015-06-03       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.